G.d. Searle & Company

Pharmacia Corporation

Lori A Schretzman

Norman A Abood

Daniel L Flynn

Roger A Nosal

Scott A Laneman

Thomas Dale Penning

Balekudru Devadas

Ish K Khanna

Daniel Paul Becker

Srinivasan Raj Nagarajan

Clara I Villamil

Mark Andrew Russell

Barbara B Chen

Nizal S Chandrakumar

Mark Laurence Boys

Hui Li

Brian M Bax

Dale P Spangler

Michael B Tollefson

Robert B Garland

Hwang-Fun Lu

Scott B Mohler

Jeffery Alan Zablocki

Thomas Edward Rogers

Masateru Miyano

Susan Landis Hockerman

Alan Frank Gasiecki

Bipinchandra N Desai

Jeffery A Zablocki

Yi Yu

Renee Huff

Kenneth Williams

Albert Khilevich

John Adam Wendt

Yaping Wang

Michael J Bennett

Hung-Fun Lu

The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &#x3b1;&#x3bd;&#x3b2;and/or the &#x3b1;&#x3bd;&#x3b2;integrin without significantly antagonizing the IIb/IIIa integrin. 

Heteroarylakanoic acids as intergrin receptor antagonists

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &#x3b1;&#x3b2;and/or the &#x3b1;&#x3b2;integrin without significantly antagonizing the IIb/IIIa or &#x3b1;&#x3b2;integrin.

Heteroarylalkanoic acids as integrin receptor antagonists

2-Amino-benzoxazinones for the treatment of viral infections

Gem-substituted &agr;v&bgr;3 antagonists

2-amino benzoxazinones for the treatment of viral infections

The present invention relates to double prodrugs of pharmacologically active glycoprotein IIb/IIIa antagonists of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl of about 2 to about 8 carbon atoms, cycloalkyl, and aralkyl; R is selected from the group consisting of alkoxy, ##STR2## wherein R.sup.50 is H or alkyl; and ##STR3## wherein R.sup.50 is H or alkyl; and pharmaceutically acceptable salts thereof.

Double prodrugs of potent GP IIb/IIIa antagonists

A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula II ##STR1## wherein R.sup.28 is selected from (a) amino substituted with one or two radicals selected from alkyl, aralkyl, heterocycoalkyl, heterocyclo, and aryl, and (b) amino acid residues and derivatives thereof; wherein R.sup.29 is selected from hydrido, alkyl, halo, ##STR2## wherein R.sup.30 is selected from alkyl, alkoxy, alkylamino, carboxyalkyl, alkoxyalkyl, alkylaminoalkyl, cycloalkyl, heterocyclo, heterocycloalkyl, heterocycloalkoxy, alkylaminoalkoxy, alkylaminoalkylamino, heterocycloalkylamino, and N-aralkylamino; wherein R.sup.31 is alkyl; wherein R.sup.32 is alkyl and aryl; or a pharmaceutically-acceptable salt thereof.

2-amino-benzoxazinones for the treatment of viral infections

Platelet aggregation inhibitors

The invention herein is directed to a process for producing a lactam of the formula ##STR1## from a methionine analog of the formula ##STR2## by treating the methionine analog with trimethylsulfonium halide or trimethylsulfoxonium halide in the presence of a base in a suitable aprotic solvent. The invention herein is further directed to the preparation of amidinophenyl pyrrolidinyl .beta.-alanine urea analogs using such methionine and lactam compounds as intermediates, which .beta.-alanine urea analogs are useful as antithrombotics.

Intermediates for amidino phenyl pyrrolidine .beta.-alanine urea analogs

Process for the preparation of amidino phenyl pyrrolidine beta-alanine

Process for the preparation of amidino phenyl pyrrolidine .beta.-alanine

Phenyl amidines derivatives useful as platelet aggregation inhibitors

Growing community of inventors

Gurnee, IL, United States of America

Lori A Schretzman